ARS Pharmaceuticals, Inc.
SPRY
$13.77
-$0.87-5.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 297,063.33% | 8,460.00% | 128.31% | -98.51% | -97.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 297,063.33% | 8,460.00% | 128.31% | -98.51% | -97.72% |
| Cost of Revenue | 1.45% | -2.20% | -13.13% | 2.73% | 16.53% |
| Gross Profit | 443.34% | 14.71% | 14.61% | -6.61% | -25.98% |
| SG&A Expenses | 51.37% | -15.94% | -1.38% | 51.80% | 155.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.54% | -12.04% | -5.48% | 32.65% | 88.81% |
| Operating Income | 95.43% | 15.59% | 5.96% | -34.56% | -95.94% |
| Income Before Tax | 115.24% | 20.32% | 15.94% | -17.23% | -56.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 114.71% | 20.32% | 15.94% | -17.23% | -56.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 114.71% | 20.32% | 15.94% | -17.23% | -56.75% |
| EBIT | 95.43% | 15.59% | 5.96% | -34.56% | -95.94% |
| EBITDA | 95.55% | 15.59% | 5.97% | -34.56% | -96.17% |
| EPS Basic | 113.92% | 28.41% | 39.29% | 34.58% | 34.60% |
| Normalized Basic EPS | 111.31% | 23.76% | 35.29% | 30.59% | 31.00% |
| EPS Diluted | 97.80% | 28.41% | 39.29% | 34.58% | 34.60% |
| Normalized Diluted EPS | 95.79% | 23.76% | 35.29% | 30.59% | 31.00% |
| Average Basic Shares Outstanding | 1.81% | 9.54% | 33.70% | 71.28% | 138.30% |
| Average Diluted Shares Outstanding | 7.54% | 9.54% | 33.70% | 71.28% | 138.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |